FDA Approval and Product Details

The FDA approved ANDA 207944 from Par Pharmaceutical on January 18, 2017. The product is a generic version of Aggrenox, containing aspirin 25mg and extended-release dipyridamole 200mg capsules, and is in the approval and marketing phase. U.S. sales began on January 30, 2017, and the current label indicates Endo USA. The key aspect of this record is that it is a generic drug approved based on bioequivalence with the reference drug, rather than a new drug clinical trial.

Mechanism of Action and Clinical Value

Aspirin irreversibly inhibits platelet cyclooxygenase-1 (COX-1), reducing thromboxane A2 production, while dipyridamole inhibits phosphodiesterase (PDE) and adenosine reuptake, reducing platelet aggregation. The indication is to reduce the risk of recurrent stroke in patients who have experienced a thrombotic transient ischemic attack (TIA) or ischemic stroke. The reference brand, Aggrenox, was developed by Boehringer Ingelheim and initially approved by the FDA in 1999. In the ESPS2 trial, Aggrenox reduced the 2-year risk of stroke by 22.1% compared to aspirin alone, 24.4% compared to dipyridamole alone, and 36.8% compared to placebo, establishing the clinical evidence for the combination.

Competitive Landscape and Market Significance

The key competing treatments for the same patient population are low-dose aspirin, clopidogrel (Plavix), and short-term dual antiplatelet therapy (DAPT) with aspirin and clopidogrel. In particular, generic clopidogrel offers the convenience of once-daily dosing and has extensive prescribing experience, which limits the market share expansion of the twice-daily aspirin and dipyridamole combination. However, the fixed-dose combination with two different mechanisms of action provides a differentiated option for preventing recurrence compared to monotherapy. In 2024, the global market for antiplatelet drugs in ischemic stroke is estimated at approximately USD 2.27 billion, making price competitiveness a key factor influencing prescribing access and insurance coverage.

Regulatory and Business Implications

The ANDA approval is not an event recognizing new efficacy but a regulatory event allowing the marketing of a low-cost alternative with equivalent quality, performance, and use to Aggrenox. It was processed as a standard generic ANDA review and did not involve an FDA Advisory Committee (AdComm) vote or separate EMA/PMDA approval. The entry of the Par product will reduce out-of-pocket costs for patients and drug costs for insurers, but high pricing power is unlikely due to multiple generic competitors and the combination of older ingredients. Therefore, the investment implications focus on stable sales of mature products, supply reliability, and cost management rather than the value of an innovative pipeline.